Navigation Links
Terminally Ill Patients Asked To Depute People To Make Decisions

A law that is coming into effect this weekend requests terminally ill patients to nominate somebody to take decisions on their behalf for their treatment//. The British Medical Association has published fresh guidance for doctors regarding this. The BMA guidelines are said to be in the best interests of the patients and are also based on the recent court judgments.

These guidelines by the BMA are concurring with the Mental Capacity Act which is coming into effect from this weekend. Dr Vivienne Nathanson who is BMA's head of science and ethics says that this is the right kind of opportunity one should use to depute someone to take decisions on their behalf when they lose capacity to take decisions.

Dr Nathanson suggests that this opportunity can be made use of by patients who are terminally ill and suffer from a chronic disease. She also feels that this piece of information could be useful to the doctors. According to Ilora Finlay, professor of palliative medicine at Cardiff University, this could provide a baseline for treatment and doctors should continue to communicate to patients on this issue.

The present guidance is the third instance of BMA publishing on this issue since 1999. It says regular updates will be issued to reflect changes in the law as they arise.
JYT
'"/>




Page: 1

Related medicine news :

1. Terminally Ill Patients Could Be Offered A Better Life
2. Terminally Ill deserves a better quality of Life
3. Terminally Ill Children Require Home Care
4. Terminally Ill Cancer Patients Are Not Getting Cash Benefits
5. Terminally Ill: End Of Life Choices
6. Report Calls For Better Implementation Of Last Wishes of Terminally Ill
7. One in Three Heart Attack Patients Have No Chest Pains
8. Amphetamines Help Recovery of Stroke Patients
9. Painkillers Do Not Shorten Dying Patients Lives
10. Patients With Filariasis More Prone To HIV Infection
11. Glivec - New Hope For CMC Patients
Post Your Comments:
(Date:12/6/2009)... NEW ORLEANS and SUNNYVALE, Calif., Dec. 6 /PRNewswire-FirstCall/ ... announced interim results from a Phase I/II study ... relapsed / recurrent non-Hodgkin,s Lymphoma (NHL) treated with ... The data were presented today at the 51st ... LA (Abstract # 2726). ,, PCI-24781 is ...
(Date:12/6/2009)... factor, researchers say , , SUNDAY, Dec. 6 (HealthDay ... the main tumor to other parts of the body ... which may prove a promising target for new drugs ... Previous studies have shown that TGFb (transforming growth factor ... new study, a team from Cancer Research UK used ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Sickle cell disease, ... blood cells, is one of the most common ... the world, including more than 70,000 Americans.(1) Research ... the American Society of Hematology highlights intriguing studies ... presents for children with this blood disorder, evaluations ...
(Date:12/6/2009)... organizations and members of the community, in cooperation with the Greater ... a holiday party. This year,s attendance is expected to soar to ... , ... (PRWEB) December 6, 2009 -- Volunteer ... VA Healthcare System in West Los Angeles, will once again create ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: ... other terminal illnesses affecting children. All proceeds from each hair ... Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, provided ... Falls Church for all guests. Hoa Lai, a DJ known ...
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
... UN report shows staggering figures on the spread of ... The Indian Government thought it was taking a very ... commonly accessed public places. This included places like the ... well educated states like Kerala. ,However, surprisingly ...
... Studies have shown that tobacco smoke can cause in children ... ,Researchers from the University of Rochester School of Medicine had ... second hand, are more at risk of being overweight and ... children in the age group of 12 to 19 years. ...
... that some older pacemakers manufactured by Guidant Corporation may ... device. The products include early generation designs that have ... years, some of the names of the affected models ... II, Discovery II, Virtus Plus II, Intelis II, and ...
... Central Drugs Standard Control Organisation (CDSCO) in India has ... action against the manufacture// of not of standard quality ... guidelines drawn out would prescribe the exact procedures to ... manufacturers by every state drug controller. ,Officials ...
... University of Texas Medical Branch at Galveston have found ... cause the allergic reactions// and asthma other than the ... factor is the damage caused by chemically hyperactive molecules ... interactions between a single pollen-carried enzyme and the cells ...
... circles as well as social circles. Every 2nd person out ... from that is always welcome. ,It was previously ... syndrome among young obese adults. ,Hyon K. Choi and colleagues ... risk of type 2 diabetes in men in a new ...
Other Medicine News:Health News:Condom Vending Machines Increasing Sexual Assaults On Women 2Health News:Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices 2Health News:New Insight Gained For Allergic Reactions 2
(Date:12/4/2009)... DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC ... has been enrolled in the company,s Phase II-b, dose ... emulsion in traumatic brain injury (TBI). Oxycyte is the ... is of invaluable importance in improving the outcome of ...
(Date:12/4/2009)... World recently highlighted a new report published ... ( PhRMA ) that identifies 97 new drugs and vaccines ... report found that the 97 products in development include ... human clinical trials or awaiting approval by the U.S. Food ...
(Date:12/4/2009)... 4 Suneva Medical, a privately-held aesthetic medical device ... Vice President and Chief Financial Officer. In this ... and administrative functions including finance, accounting, IT, IR, administration ... the Company,s senior management team. ,, "One of ...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Stem cell applications and research highlight NJITs first Research Cafe 10091 1NIH announces 115 awards to encourage high risk research and innovation 10088 1NIH announces 115 awards to encourage high risk research and innovation 10088 2Baptist Receives Chest Pain Accreditation for the Second Time in the Metro Jackson Area 58271 1Baptist Receives Chest Pain Accreditation for the Second Time in the Metro Jackson Area 58271 2Baptist Receives Chest Pain Accreditation for the Second Time in the Metro Jackson Area 58271 3
... 3 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... launched Clarithromycin Extended-Release,Tablets, USP in the 500 mg ... to Abbott,s Biaxin(R),XL, which is indicated to treat ... to be caused by susceptible bacteria. For the ...
... activity in vivo, SAN DIEGO, Jan. 3 ... today from two studies of,ANA598, a non-nucleoside inhibitor of ... model of chronic HCV infection., Two animals chronically ... of ANA598 at 30 mg/kg for four days. A ...
Other Medicine Technology:Watson Launches Generic Biaxin(R) XL 2Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 4
... utilizes the same proven materials found in ... SR™ Hand Implant System provides advantages not ... bone resection, surface replacement of the diseased ... repositioning of the ligamentous soft tissues, and ...
... of the NeuFlex™ MCP and/or ... based on numerous research studies ... of the MCP/PIP joint. This ... or the phalanx, by settling ...
... The Blackstone Anterior Cervical Plate ... plate implantation. The innovative design ... plate prevents screw back-out. The ... placement. Simple, reliable instrumentationincluding innovations ...
... Engineered to closely match the natural ... anatomical design. Titanium construction incorporates an ... snap-fit screw design prevents screws from ... the need for X-ray control of ...
Medicine Products: